Hair Multiplication: RepliCel Life Sciences Inc. Provides Update on First Human Study
In an attempt to become the first biotechnology company to offer a reliable hair multiplication therapy, RepliCel Life Sciences Inc. recently released an update on its first human clinical research trial.
During the trial, 19 individuals (10 male and 9 female hair loss sufferers) were treated with a series of Replicel hair multiplication and placebo injections in various regions of the scalp.
To assess the success of the hair multiplication injections, the researchers will analyze all injected areas of the scalp at maturation and note where new hair growth is seen. If a greater amount of new growth is observed in the hair multiplication injection sites (compared to the placebo injection sites), then the product may have some merit in actually generating new hair.
During the recent 6 month update, Replicel evaluated the health and well-being of 17 of the 19 study participants and determined all patients were healthy and aren’t experiencing adverse effects from the treatment. Because of this, Replicel is on track to review the actual efficacy of the treatments in April 2012 and release final results in late 2013.
Check back for future RepliCel updates. To review the official press release, click here.
_______________
Blake – aka Future_HT_Doc
Editorial Assistant and Forum Co-Moderator for the Hair Transplant Network, the Hair Loss Learning Center, the Hair Loss Q&A Blog, and the Hair Restoration Forum
Follow our community on Twitter
Watch hair transplant videos on YouTube
Technorati Tags: hair multiplication, RepliCel, hair loss, Replicel hair multiplication, hair growth
